Tests transanal irrigation for sleep trouble after rectal cancer surgery
Tests rectal washing to improve sleep in adults with bowel symptoms after rectal cancer surgery.
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery (TraLARS)
- Status
- Recruiting
- People taking part
- 52 people, planned
- Started
- 6 Dec 2023
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Transanal Irrigation (TAI)
- Record updated
- 24 January 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had low rectal cancer surgery at least 24 months ago and now have sleep problems from bowel symptoms (LARS). It tests transanal irrigation.
- Age
- 19 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Rectal cancer treated with low or ultra-low anterior resection (within 15cm (5.9 in) from the anal verge), with major LARS score and an ISI score of 3 or 4.
- Earlier treatment
- At least 24 months after surgery. Any cancer treatment after surgery must be finished. After bowel restoration surgery, at least 6 months must have passed. After long-course radiotherapy before surgery, at least 18 months. No medication for LARS in the last month.
Main reasons for not taking part
- Cancer that came back or has spread
- Permanent colostomy needed
- Radiation therapy after surgery
- Inflammatory bowel disease (IBD)
- Constipation or diarrhea not controlled by medication
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adults aged 19 years and above
- Patients who have undergone low or ultra-low anterior resection surgery for rectal cancer (within 15cm from the anal verge)
- Patients at least 24 months post-surgery (excluding those with incontinence, patients who have undergone postoperative cancer treatment should have completed treatment, and patients who have undergone bowel restoration surgery should be at least 6 months post-surgery, or for patients who received long-course preoperative radiotherapy, at least 18 months post-surgery)
- Patients evaluated with a major LARS score who also have an ISI score of 3 or 4
- Patients who comprehend and have the ability to participate in this clinical trial
Who cannot take part
- Patients currently taking medication for LARS within the last month
- Patients with a history of prior surgery for colorectal cancer
- Patients with concomitant metastatic colorectal cancer
- Patients with symptoms of constipation or diarrhea not controlled by medication
- Patients allergic to the investigational drug
- Patients with recurrent colorectal cancer
- Patients who have undergone postoperative cancer radiation therapy
- Patients with underlying conditions not controlled by internal medical treatment
- Patients with inflammatory bowel disease (IBD)
- Patients requiring permanent colostomy
- Patients with preoperative symptoms of fecal incontinence
- Patients deemed unsuitable for clinical trial participation by the principal investigator and study personnel
- Patients with ISI scores of 1 or 2
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 80 years old?
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaContact: Seung-Bum Ryoo, MD, PhDTaking people
About the trial
What the trial wants to find out
The preservation surgery of the anal sphincter muscle has become the standard procedure in the treatment of rectal cancer and, thanks to advancements in surgical techniques, can now be performed for tumors located closer to the anus. This method allows patients to avoid a permanent artificial anus, maintaining continuity of the intestines and enabling bowel movements through the anus, making it a highly preferred procedure. Furthermore, advancements in various tumor treatments have led to improved long-term survival rates.
Read full original descriptionShow less
Preservation surgery of the anal sphincter muscle is commonly used in the treatment of rectal cancer, resulting in approximately 90% of patients experiencing changes in bowel habits after surgery. These changes include characteristic diarrhea, urgent bowel movements, frequent bowel movements, and fecal incontinence, collectively known as Anterior Resection Syndrome (ARS). Particularly in the case of low rectal cancer, it often manifests as Low Anterior Resection Syndrome (LARS). These symptoms are most severe immediately after surgery, generally persisting in a significant degree for 1-2 years, with some improvement over time. However, for many patients, LARS remains a lifelong challenge, significantly impacting their quality of life. Nighttime symptoms of LARS, in particular, have a profound effect on sleep quality, potentially leading to a decline in overall quality of life.
Currently, there is no definitive method to completely cure LARS, and the available approaches focus on empirical treatments or short-term symptom control using medications such as loperamide.
Loperamide directly affects the neuromuscular system of the intestine, reducing its motility. This prolongs the time food stays in the intestine, allowing sufficient absorption of moisture and electrolytes, consequently reducing symptoms of diarrhea. Loperamide is available in two forms: loperamide oxide and loperamide hydrochloride. While loperamide oxide products like Arestal® were prescribed by doctors until August 2017, the approval was revoked, leaving loperamide hydrochloride as the only form used domestically. It comes in a single product containing 2 mg of loperamide hydrochloride and a combination product with 0.25 mg of loperamide hydrochloride, a sterilizing agent in the intestine (e.g., acrylonitrile, berberine), and an antispasmodic.
Transanal irrigation (TAI) is a method where patients self-administer water into the rectum through an enema, physically cleansing the anus and rectum. This technique is often used for patients with chronic constipation or fecal incontinence. TAI has proven beneficial, particularly in improving symptoms for patients experiencing bowel dysfunction following sphincter-preserving surgery, especially for those who underwent low anterior resection.
However, there is currently no research on the utility and safety of TAI for LARS patients, specifically addressing whether it can improve the nighttime symptoms associated with LARS syndrome and enhance sleep quality. Therefore, this study aims to investigate the impact of TAI on the quality of sleep in patients with nighttime symptoms of LARS syndrome.
The 2 groups in the trial
- Loperamide groupNo study treatment, for comparison
The group only takes loperamide in the evening.
- Loperamide + Transanal irirgation groupTreatment being tested
The group takes Loperamide in the evening and undergoes Transanal irrigation before bedtime.
Treatment: Transanal Irrigation (TAI)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery: A Multicenter Prospective Randomized Controlled Trial (TraLARS)
- Plain-language title
- Tests transanal irrigation for sleep trouble after rectal cancer surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06222255, who can take part
- Record updated
- 24 January 2024